3Ishimura T, Fujisawa M, Isotani S, et al. Transforming growth factor-beta1 expression in early biopsy specimen predicts long-term graft function following pediatric renal transplantation [J]. Clin Transplant,2001,15 ( 3 ) : 185-191.
4CitterioF, Pozzetto U, Romagnoli J, et al. Plasma levels of transforming growth factor-betal in renal transplant recipients receiving different immunosuppressive regimens [J]. Transplant Proc ,2004,36 ( 3 ) :698-699.
5Nikolova PN, Ivanova MI, Mihailova SM, et al. Cytokine gene polymorphism in kidney transplantation-impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome [J]. Transpl Immunol, 2008,18 ( 4 ) : 344 -348.
6Nelson RG, Tuttle KR. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD [ J]. Blood Pu- rif,2007 ;25 ( 1 ) : 1 12-4.
7Sierra C, Dela Sierra A. Early detection and management of the high-risk patient with elevated blood pressure[ J]. Vase Health Risk Manag,2008 ; 4(2) :289-90.
8Frank P, Kay H, Beate K,et al. Rosiglitazone improves glomerular hy- perfihration, renal endothelial dysfunction, and microalbuminuria of in- cipient diabetic nephropathy in patients [ J ]. Diabetes, 2005 ; 54 ( 7 ) : 2206-11.
10Han Y,Zhu G,Han L,et al.Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease[J].Journal of the American College of Cardiology,2014,63(1):62-70.
